Friday 16 October 2026
Export CDXS’s income statement to Excel — free account
Codexis, Inc.
CDXS Healthcare Biotechnology
Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.
1.25
0.11
−8.09%
Follow CDXS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.16 | 2.02 | 1.89 | 2.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.59) | 7.07 | (11.25) | (21.34) | |
P/B ratio |
5.71 | 2.81 | 3.42 | 6.24 | |
Price to Tangible BV |
6.10 | 2.96 | 3.63 | 6.75 | |
EV/Sales |
3.79 | 1.47 | 1.57 | 2.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.59) | (5.34) | (6.56) | (17.71) | |
EV/FCF |
(3.26) | (4.34) | (5.56) | (15.15) | |
Quick Ratio |
3.62 | 3.51 | 4.93 | 2.66 | |
Current Ratio |
4.12 | 3.82 | 5.36 | 3.06 | |
Net Debt/EBITDA |
1.13 | (3.09) | 4.14 | 2.31 | |
Debt/Assets |
32.05% | 27.14% | 31.29% | 28.17% | |
Debt/Equity |
1.03 | 0.79 | 0.94 | 1.03 | |
Asset Turnover |
0.39 | 0.47 | 0.60 | 0.60 | |
Operating CF/Net income |
0.39 | 2.09 | 1.51 | 0.80 | |
Capex/Depreciation |
(0.10) | (0.27) | (0.09) | (0.46) | |
Interest Coverage |
(14.67) | 6.62 | (6.23) | (8.63) | |
Research and Development Expense of Revenue |
161.24% | 30.12% | 75.08% | 78.48% | |
Selling, General and Administrative Expense of Revenue |
130.42% | 28.74% | 64.13% | 73.26% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
29.22% | 5.65% | 9.37% | 10.61% | |
Graham Net Nets |
(0.04) | 0.00 | (0.04) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(31.15%) | (31.90%) | (22.70%) | (15.04%) | |
Free Cash Flow Yield |
(28.00%) | (16.79%) | (14.95%) | (5.91%) | |
Revenue per Share |
0.10 | 0.45 | 0.17 | 0.16 | |
Operating CF per Share |
(0.09) | 0.23 | (0.14) | (0.11) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.09) | 0.22 | (0.15) | (0.12) | |
Cash per Share |
0.66 | 0.90 | 0.72 | 0.61 | |
Shareholders Equity per Share |
0.43 | 0.58 | 0.48 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.43 | 0.58 | 0.48 | 0.36 | |
Free Cash Flow |
(7.88) | 19.57 | (13.33) | (10.53) | |
Working Capital |
57.72 | 71.50 | 64.80 | 48.41 | |
Capital Expenditures |
(0.18) | (0.52) | (0.18) | (0.88) | |
Net Current Asset Value |
(9.22) | (0.45) | (6.49) | (15.18) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.36 | 12.35 | 8.69 | 11.26 | |
Average Payables |
3.32 | 2.20 | 4.09 | 2.04 | |
Average Inventory |
2.02 | 1.81 | 1.89 | 1.77 | |
Average Assets |
136.07 | 148.40 | 129.13 | 129.15 | |
Average Common Equity |
55.97 | 58.73 | 46.43 | 44.29 |
Columns are period end dates